On page 2307, in Figure 3, the column “No. of Patients with an Event” should have been omitted. The corrected Figure 3 is shown below.
EFS at 36 months in key subgroups. EFS rate was estimated per Kaplan-Meier method at 36 months among baseline patient and disease characteristics in response-evaluable patients (n = 37). Lower CI and upper CI were 95% confidence limits of EFS rate from Kaplan-Meier estimates. The dotted vertical line presents the point estimate of overall population. ABC, activated B cell; C-MYC, myc proto-oncogene protein; ECOG, Eastern Cooperative Oncology Group; GCB, germinal-center type B cell; PD, progressive disease; PR, partial response; SD, stable disease.
EFS at 36 months in key subgroups. EFS rate was estimated per Kaplan-Meier method at 36 months among baseline patient and disease characteristics in response-evaluable patients (n = 37). Lower CI and upper CI were 95% confidence limits of EFS rate from Kaplan-Meier estimates. The dotted vertical line presents the point estimate of overall population. ABC, activated B cell; C-MYC, myc proto-oncogene protein; ECOG, Eastern Cooperative Oncology Group; GCB, germinal-center type B cell; PD, progressive disease; PR, partial response; SD, stable disease.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal